Independent Non-Executive Director of Radiopharm Theranostics Picks Up 48% More Stock

Yahoo

01-06-2025

Even if it's not a huge purchase, we think it was good to see that Ian Turner, the Independent Non-Executive Director of Radiopharm Theranostics Limited (ASX:RAD) recently shelled out AU$87k to buy stock, at AU$0.029 per share. That purchase might not be huge but it did increase their holding by 48%.
Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit.
The MD, CEO & Director Riccardo Canevari made the biggest insider purchase in the last 12 months. That single transaction was for AU$241k worth of shares at a price of AU$0.031 each. So it's clear an insider wanted to buy, even at a higher price than the current share price (being AU$0.024). It's very possible they regret the purchase, but it's more likely they are bullish about the company. We always take careful note of the price insiders pay when purchasing shares. As a general rule, we feel more positive about a stock if insiders have bought shares at above current prices, because that suggests they viewed the stock as good value, even at a higher price.
In the last twelve months insiders purchased 22.43m shares for AU$772k. But insiders sold 1.50m shares worth AU$43k. Overall, Radiopharm Theranostics insiders were net buyers during the last year. Their average price was about AU$0.034. These transactions suggest that insiders have considered the current price attractive. You can see the insider transactions (by companies and individuals) over the last year depicted in the chart below. If you click on the chart, you can see all the individual transactions, including the share price, individual, and the date!
Check out our latest analysis for Radiopharm Theranostics
Radiopharm Theranostics is not the only stock that insiders are buying. For those who like to find small cap companies at attractive valuations, this free list of growing companies with recent insider purchasing, could be just the ticket.
Looking at the total insider shareholdings in a company can help to inform your view of whether they are well aligned with common shareholders. We usually like to see fairly high levels of insider ownership. From our data, it seems that Radiopharm Theranostics insiders own 11% of the company, worth about AU$6.3m. Overall, this level of ownership isn't that impressive, but it's certainly better than nothing!
It's certainly positive to see the recent insider purchase. We also take confidence from the longer term picture of insider transactions. However, we note that the company didn't make a profit over the last twelve months, which makes us cautious. We would certainly prefer see higher levels of insider ownership but analysis of the insider transactions suggests that Radiopharm Theranostics insiders are expecting a bright future. While it's good to be aware of what's going on with the insider's ownership and transactions, we make sure to also consider what risks are facing a stock before making any investment decision. When we did our research, we found 4 warning signs for Radiopharm Theranostics (2 make us uncomfortable!) that we believe deserve your full attention.
But note: Radiopharm Theranostics may not be the best stock to buy. So take a peek at this free list of interesting companies with high ROE and low debt.
For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.